Vutrisiran Demonstrates Consistent Cardiovascular Benefits Across All Age Groups in ATTR-CM Patients
核心洞察
Vutrisiran significantly reduced mortality and cardiovascular events in patients with transthyretin amyloid cardiomyopathy (搜索) across all age groups, including those 80 years and older.
The HELIOS-B trial analysis of 654 patients showed consistent treatment benefits regardless of age, with no significant interaction between treatment effect and patient age.
Patients receiving vutrisiran maintained functional capacity and quality of life improvements compared to placebo, with comparable safety profiles across age categories.
A prespecified age-based analysis of the phase 3 HELIOS-B trial has demonstrated that vutrisiran (Amvuttra; Alnylam Pharmaceuticals (搜索)) provides consistent cardiovascular benefits across all age groups in patients with transthyretin amyloid cardiomyopathy (搜索) (ATTR-CM (搜索)), including those 80 years and older. The findings, published in the European Journal of Heart Failure (搜索), challenge traditional concerns about treating elderly patients with this progressive cardiac condition.
Consistent Benefits Across Age Spectrum
The analysis examined outcomes among 654 patients with ATTR-CM (搜索) stratified into three age groups: younger than 75 years (39%), 75 to under 80 years (31%), and 80 years or older (30%). The mean age of the overall population was 75 years. Across all age categories, vutrisiran consistently reduced the primary composite outcome of all-cause mortality and recurrent cardiovascular events compared with placebo, with no significant interaction between treatment effect and age (p interaction = .50).
Importantly, patients 80 years and older—who had more advanced disease at baseline, higher cardiac biomarkers, and lower functional capacity—experienced similar relative risk reductions to younger participants. Continuous age modeling confirmed that treatment efficacy remained stable across the full age spectrum, suggesting no reduction in benefit among older adults.
Advanced Disease Population Shows Robust Response
Older participants were more likely to have wild-type ATTR-CM (搜索) and advanced disease stage, reflecting real-world epidemiology. They also had higher levels of NT-proBNP and troponin, markers associated with worse prognosis, underscoring the clinical significance of achieving consistent benefits in this group.
"Older adults with ATTR-CM (搜索) face a disproportionate burden of disease, including higher risk of death and hospitalization, that significantly contribute to health system costs," the authors explained. "Additionally, the high burden of comorbidities in older patients associated with frailty, polypharmacy, and the limited remaining lifespan, leads to physician concerns about the possibility of attenuated treatment effects and potential safety issues."
Functional Outcomes and Quality of Life Preserved
Beyond clinical events, vutrisiran preserved physical function and health-related quality of life across all age groups. Patients receiving vutrisiran showed improvements in 6-minute walk distance and Kansas City Cardiomyopathy Questionnaire overall summary scores compared with placebo, with no evidence that age influenced these functional outcomes.
The HELIOS-B trial included an older population and permitted broader background therapy use than previous ATTR-CM (搜索) studies, with approximately 40% of participants already taking tafamidis at trial entry. The study demonstrated statistically significant results across all major endpoints, including reductions in all-cause mortality and cardiovascular hospitalizations, with notable benefit observed both in monotherapy and combination-therapy subgroups.
Safety Profile Remains Favorable
Rates of serious adverse events and treatment discontinuation were comparable between vutrisiran and placebo across age categories, and older patients did not experience higher safety risks. Common adverse events—such as cardiac failure and arrhythmias—reflected the underlying disease rather than the drug itself.
"There is a historical undertreatment of elderly patients with heart failure (搜索), likely due to several factors, including concerns regarding frailty, polypharmacy, limited remaining life expectancy, and perceived marginal benefit," the authors wrote. "Our findings challenge these assumptions and suggest that age alone should not preclude the initiation of an effective treatment like vutrisiran in elderly patients with ATTR-CM (搜索)."
Clinical Implications for Treatment Decisions
The findings supported FDA approval of vutrisiran for ATTR-CM (搜索) and represent a meaningful therapeutic advancement for patients across the age spectrum. ATTR-CM is a progressive, infiltrative cardiomyopathy caused by misfolded transthyretin (搜索) protein deposits in the heart and other organs, primarily affecting older adults who face high risks of heart failure (搜索), hospitalization, and death.
"Vutrisiran treatment led to a consistent reduction in death and cardiovascular events, preservation of functional status, and maintenance of quality of life, with a favorable safety profile," the authors concluded. "These findings reinforce that age alone should not be a barrier to offering effective disease-modifying therapies for ATTR-CM (搜索) and support the use of vutrisiran in elderly patients, who represent a substantial and growing proportion of the affected population."
The authors noted that while the HELIOS-B trial was not powered to definitively compare individual age groups, the analysis was prespecified and provides important evidence for clinical decision-making in this vulnerable patient population.